Which migraine drug do patients prefer? large survey reveals Real-World results

NCT ID NCT06680206

Summary

This study analyzed survey data from over 1,300 people with migraines to compare two common acute treatments: rimegepant (like Nurtec) and triptans. Researchers looked at which treatment led to better patient satisfaction, quality of life, and less impact on work and daily activities. The goal was to understand real-world patient experiences, not to test a new drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

Conditions

Explore the condition pages connected to this study.